Probiotics Supplementation Therapy for Pathological Neonatal Jaundice: A Systematic Review and Meta-Analysis

Zhe Chen1,2,3, Lingli Zhang1,2,3, Linan Zeng1,2,3

  • 1Department of Pharmacy, West China Second University Hospital, Sichuan UniversityChengdu, China.

Insights

Probiotics supplementation effectively treats pathological neonatal jaundice by reducing bilirubin levels and shortening recovery time. This meta-analysis confirms probiotics as a safe and beneficial therapy for newborns with jaundice.

Area of Science:

  • Neonatal Medicine
  • Gastroenterology
  • Microbiology

Background:

  • Neonatal jaundice affects 2.4-15% of newborns, with limited evidence on probiotic efficacy.
  • Probiotics may improve jaundice recovery by regulating gut bacteria and enhancing immunity.
  • This study systematically evaluates probiotics for pathological neonatal jaundice.

Purpose of the Study:

  • To assess the efficacy and safety of probiotic supplementation for pathological neonatal jaundice.
  • To analyze the impact of probiotics on bilirubin levels, jaundice fading time, and treatment duration.

Main Methods:

  • A systematic review and meta-analysis of randomized controlled trials (RCTs) published up to December 2016.
  • Searched multiple databases including PubMed, Embase, Cochrane Library, CNKI, Wan Fang, CBM, and VIP.
  • Assessed risk of bias using the Cochrane tool and analyzed data with Review Manager 5.3.

Main Results:

  • Included 13 RCTs with 1067 neonates; probiotics showed significant efficacy (RR: 1.19).
  • Probiotics reduced total serum bilirubin levels at 3, 5, and 7 days.
  • Shortened jaundice fading time, phototherapy duration, and hospitalization duration; no serious adverse events reported.

Conclusions:

  • Probiotic supplementation is an effective and safe treatment for pathological neonatal jaundice.
  • Probiotics demonstrate significant benefits in reducing bilirubin levels and accelerating recovery.
  • Further research may explore specific probiotic strains and optimal dosages.

Related Concept Videos

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
972
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
852
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
289
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
377
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
407
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
849